Ipasta: New Hope for Diabetes Retinal Neural Disorder

Diabetes, a chronic disease that spreads worldwide, acts like a hidden killer, quietly attacking various organs and systems of the human body. Among them, diabetes neurosis is one of the chronic complications common to diabetes, while retina neurosis is a serious manifestation of diabetic neurosis in the eye, which threatens the patient ‘ s vision at all times, like a high sword of Damocles. Diabetes retinal neurosis has a more complex mechanism, which is linked mainly to long-term high blood sugar metabolic disorders, increased oxidation stress, neuromorbidation of blood vessels and lack of neurogrowth factors. In a state of high blood sugar, polyol artery is activated, the accumulation of intracellular pear alcohol leads to neurological oedema and variability; at the same time, the oxidation-resilient free radicals damage the structure and functioning of the neurological membrane; the neurological hysteresis causes neurological hemorrhaging, hypoxia, which eventually leads to damage to and collapse of retina neurological cells and their axles, as well as to signs of loss of vision, loss of vision and chromosomal abnormalities, which seriously affect the quality of life and may even lead to blindness, placing a heavy psychological and economic burden on patients and their families. Ipas, a new type of formaldehyde reduction enzyme inhibitor, has a unique role to play in the treatment of diabetes membrane neurosis. The formaldehyde reduction enzyme is the key speed limit enzyme in the polyol route, which is activated in a high blood sugar environment, resulting in a large conversion of glucose to pearol and cell accumulation. The Ipas is uniquely capable of inhibiting the activity of formaldehyde reduction enzymes, reducing the generation of pear alcohol, thus effectively improving the metabolic disorders of neurocells, reducing cell oedema and variability, mitigating oxidizing stress and promoting the repair and regeneration of neurons. Numerous clinical studies have provided strong evidence of the effectiveness of Ipas in the treatment of retinal neurosis of diabetes. A multi-centre, random, double-blind, placebo control experiment includes [specified] cases of diabetes membrane neuropaths, which are randomly divided into ipastra treatment groups and placebo control groups for [X] months. The results showed a significant improvement in the vision of treatment group patients compared to baseline levels, a marked improvement in the loss of vision, an increase in the thickness of the retinal neural fibre layer and a decrease in the number of neural cytocellular deaths; and varying degrees of progress in the condition of placebo control group patients. Another study compares Ipas ‘ s joint conventional sugar treatment with the purely conventional sugar treatment ‘ s efficacy in the case of patients with retinal neuroses of diabetes. Following [X] months of observation, the reduction of the incubation period and the increase in the wavelength of the visual induction level of patients in the joint treatment group indicate an improvement in the retina neurotransmission function; at the same time, the reduction in the degree of ophthalmosis of patients and the decrease in the number of microvascular tumours, haemorrhage points, etc., are statistically significant in comparison to the simple sugar treatment group. In terms of safety, Ipas generally performed well, with minor adverse effects and a low incidence. Common adverse effects include gastrointestinal discomfort, such as nausea, vomiting and appetite, and generally light symptoms that do not affect continued treatment. A small number of patients may have allergies such as skin itching, rashes, etc., which are usually self-mitigated after a stoppage. In addition, the Ipas had a small effect on liver and kidney function, and at regular treatment doses, the liver and kidney function indicators for patients generally did not change significantly. Ipas has a significant efficacy and good safety in the treatment of diabetes membranes. It is able to break the mechanisms for the occurrence of retinal neuroses of diabetes mellitus from multiple links, improves the visual and retinal neurosis of patients and slows progress. However, we should also recognize that the treatment of retinal neuroses of diabetes is a long-term and integrated process, and that Ipas, as part of a comprehensive treatment programme, should be combined with strict blood sugar control, blood pressure management, blood resin regulation and other eye protection measures in order to be more effective and to provide greater benefits to patients with retinal neuroses of diabetes mellitus, helping them to guard the “window” of their hearts and to embrace a clear and colourful world.